Serena Williams' suggestion that injectable weight loss drugs could have helped her in tennis is part of an ongoing ...

A study has found that adults with obesity taking GLP-1 receptor agonists may face significantly lower risk of developing certain cancers. The cohort study was led by researchers from the Indiana ...

Ozempic and other GLP-1 weight-loss medications are seeing explosive growth in popularity, but they’re also facing billions ...

The FDA cleared the first glucose monitoring system specifically designed for weight management from Signos, providing a new ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Serena Williams broke her silence about her weight loss journey, revealing she used medication to help her lose 31 pounds.

Dr Shazia Malik - a consultant obstetrician and gynaecologist for The Portland Hospital - discussed the pros and cons of ...

Serena Williams shared a bikini pic after losing 31 pounds with GLP-1 medication, reflecting on her health challenges and ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Discover why Hims & Hers Health's subscriber growth, profitability, and telehealth expansion make it a strong buy with a ...

Tennis star Serena Williams' candor about her GLP-1 use may help dispel the pesky health inaccuracy that weight loss is a ...

They found that visceral adipose tissue volume and liver fat fraction had particularly strong relationships with ...